The response rate was also significantly greater in the FOLFOX4 with cetuximab group ( 51.3 % vs. 37.5 % , respectively ; odds ratio , 1.76 ; 95 % CI , 1.11-2 .78 ; P = .0160 ) , although overall survival was comparable .